CT is sufficient for certain lung cancer follow-ups

Radiology departments should adopt CT follow-ups of lung cancers that manifest in nonsolid nodules, according to a study published in Radiology.

Researchers from the Mount Sinai Center in New York assert that the current standard of a biopsy for a follow-up exam is unnecessary due to the nearly 100 percent survival rate of those who undergo resection.

Even when nonsolid nodules transitioned to a more dangerous type of lesion, no lung cancers were found to progress beyond stage I in a retrospective study using more than 27,000 National Lung Screening Trial participants. Nearly 10 percent of subjects had a nonsolid nodule identified during screening, but they had a 100 percent long-term cancer-specific (NSN) survival rate. While 27 patients with a NSN died, the cause of death was most likely from a different lesion.

“We think that we have enough data now to say that these nodules can safely be followed by annual CT scans and do not have to be biopsied or treated right away,” co-author Claudia I. Henschke, MD, PhD, said in a press release. “Survival remains 100 percent as long as the nodules remain nonsolid, and for those that ultimately do progress, the one-year follow-up interval is short enough that they still remain entirely curable.”

As a Senior Writer for TriMed Media Group, Will covers radiology practice improvement, policy, and finance. He lives in Chicago and holds a bachelor’s degree in Life Science Communication and Global Health from the University of Wisconsin-Madison. He previously worked as a media specialist for the UW School of Medicine and Public Health. Outside of work you might see him at one of the many live music venues in Chicago or walking his dog Holly around Lakeview.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.